SG11201908328XA - Control of total afucosylated glycoforms of antibodies produced in cell culture - Google Patents

Control of total afucosylated glycoforms of antibodies produced in cell culture

Info

Publication number
SG11201908328XA
SG11201908328XA SG11201908328XA SG11201908328XA SG 11201908328X A SG11201908328X A SG 11201908328XA SG 11201908328X A SG11201908328X A SG 11201908328XA SG 11201908328X A SG11201908328X A SG 11201908328XA
Authority
SG
Singapore
Prior art keywords
international
cell culture
glycoforms
pct
antibodies produced
Prior art date
Application number
Other languages
English (en)
Inventor
Chung-Jr Huang
Prince Bhebe
Madiha Khurshid
Li Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201908328XA publication Critical patent/SG11201908328XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
SG11201908328X 2017-03-14 2018-03-14 Control of total afucosylated glycoforms of antibodies produced in cell culture SG11201908328XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471347P 2017-03-14 2017-03-14
PCT/US2018/022388 WO2018170099A1 (fr) 2017-03-14 2018-03-14 Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire

Publications (1)

Publication Number Publication Date
SG11201908328XA true SG11201908328XA (en) 2019-10-30

Family

ID=61873969

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908328X SG11201908328XA (en) 2017-03-14 2018-03-14 Control of total afucosylated glycoforms of antibodies produced in cell culture

Country Status (10)

Country Link
US (1) US20200131518A1 (fr)
EP (1) EP3596225A1 (fr)
JP (2) JP2020513813A (fr)
CN (1) CN110418846A (fr)
AU (2) AU2018235928B2 (fr)
CA (1) CA3056011A1 (fr)
IL (1) IL269197A (fr)
MA (1) MA47775A (fr)
SG (1) SG11201908328XA (fr)
WO (1) WO2018170099A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite
EP4034556A1 (fr) * 2019-09-26 2022-08-03 Amgen Inc. Procédés de production de compositions d'anticorps
WO2022081824A1 (fr) 2020-10-15 2022-04-21 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CN113584061B (zh) * 2021-07-30 2022-09-23 中国人民解放军空军军医大学 一种双途径拮抗pcsk9的重组基因、载体、外泌体及制备方法和应用
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
SK1499A3 (en) 1996-07-19 1999-08-06 Amgen Inc Analogs of cationic proteins
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
IL132304A0 (en) 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2251120T3 (es) 1997-12-17 2006-04-16 Immunex Corporation Glicoproteinas de superficie celular asociadas a los linfomas b humanos-ulbp, adn y polipeptidos.
IL136696A0 (en) 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
IL137037A0 (en) 1998-01-23 2001-06-14 Immunex Corp Acpl dna and polypeptides
CA2337100C (fr) 1998-08-07 2011-09-20 Immunex Corporation Polypeptides des molecules d'adhesion des cellules dendritiques lymphoides (ldcam) et polynucleotides codant lesdits polypeptides
IL140938A0 (en) 1998-08-07 2002-02-10 Immunex Corp Molecules designated b7l-1
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
JP2004508043A (ja) 2000-09-05 2004-03-18 アムジェン　インコーポレイテッド Ｔｎｆレセプター様分子およびその使用
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
WO2003024389A2 (fr) 2001-07-30 2003-03-27 Immunex Corporation Imx97018, polypeptide humain de type ataxine-1
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005536180A (ja) 2001-12-03 2005-12-02 アブジェニックス・インコーポレーテッド 自己免疫疾患の治療および移植拒絶の処置に使用する抗ｃｄ４５ｒｂ抗体
WO2003048328A2 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
ATE394121T1 (de) 2001-12-28 2008-05-15 Amgen Fremont Inc Verwendung von antikörpern gegen das muc18- antigen
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
CA2481074A1 (fr) 2002-04-05 2003-10-23 Amgen Inc. Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl
RU2339647C2 (ru) 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
DK2213685T3 (en) 2002-09-06 2014-03-03 Medarex Llc Therapeutic anti-IL-1R1 monoclonal antibody
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
ES2344789T5 (es) 2003-05-15 2017-06-14 Wyeth Llc Alimentación restringida de glucosa para el cultivo de células animales
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
MXPA06000974A (es) 2003-07-25 2006-08-31 Amgen Inc Antagonistas y agonistas de ldcam y metodos para su uso.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005016111A2 (fr) 2003-08-08 2005-02-24 Abgenix, Inc. Anticorps diriges vers l'hormone parathyroide et leurs utilisations
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
CA2561861A1 (fr) 2004-04-23 2005-12-15 Amgen Inc. Anticorps de l'angiogenese inhibant des domaines de cd148
KR20070007884A (ko) 2004-04-23 2007-01-16 암젠 인크 Ｃｄ148의 혈관신생 억제 도메인의 항체
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2587903A1 (fr) 2004-11-17 2006-05-26 Amgen Fremont Inc. Anticorps monoclonaux entierement humains diriges contre l'il-13
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1868647A4 (fr) 2005-03-24 2009-04-01 Millennium Pharm Inc Anticorps se liant à ov064 et leurs méthodes d'utilisation
MX2007013217A (es) 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5142998B2 (ja) 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
PL2960253T3 (pl) 2005-09-07 2018-11-30 Amgen Fremont Inc. Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
JP5302007B2 (ja) 2005-12-13 2013-10-02 アストラゼネカ アクチボラグ インスリン様増殖因子に特異的な結合タンパク質およびその使用
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
MX2008014710A (es) 2006-05-19 2009-02-12 Amgen Inc Anticuerpos para coronavirus del sars.
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
PE20081899A1 (es) 2007-04-02 2009-01-26 Pfizer Anticuerpos anti-ige
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2261254A3 (fr) 2007-12-21 2011-04-13 Amgen, Inc Anticorps anti-amyloïdes et leurs utilisations
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2408816B1 (fr) 2009-03-20 2019-09-04 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2013114167A1 (fr) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition de glycoforme
WO2013114164A1 (fr) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation
EP2765197A1 (fr) 2013-02-11 2014-08-13 ETH Zurich Capteur de pH de concepteur en tant que commande transgène universelle
SG10201912081RA (en) * 2014-01-29 2020-02-27 Amgen Inc Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
US10590455B2 (en) * 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
WO2015128793A1 (fr) * 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited Procédé pour modifier une composition de glycoprotéine afin d'obtenir une forte teneur en mannose et une galactosylation réduite
CN106164662B (zh) 2014-03-31 2019-06-25 株式会社堀场制作所 电极、复合电极、液体分析仪
WO2016089919A1 (fr) * 2014-12-01 2016-06-09 Amgen Inc. Procédé de manipulation du taux de contenu de glycane d'une glycoprotéine

Also Published As

Publication number Publication date
US20200131518A1 (en) 2020-04-30
CA3056011A1 (fr) 2018-09-20
WO2018170099A1 (fr) 2018-09-20
JP2023055711A (ja) 2023-04-18
CN110418846A (zh) 2019-11-05
IL269197A (en) 2019-11-28
AU2023285706A1 (en) 2024-01-18
EP3596225A1 (fr) 2020-01-22
JP2020513813A (ja) 2020-05-21
AU2018235928B2 (en) 2023-09-21
AU2018235928A1 (en) 2019-09-26
MA47775A (fr) 2020-01-22

Similar Documents

Publication Publication Date Title
SG11201908328XA (en) Control of total afucosylated glycoforms of antibodies produced in cell culture
SG11201811405QA (en) Improved differentiation method
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201908540PA (en) Stable antibody formulation
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907916TA (en) Compounds and compositions for intracellular delivery of therapeutic agents
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201903089RA (en) Aav delivery of nucleobase editors
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201811318XA (en) Respiratory interface
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806398YA (en) Optimized factor viii genes
SG11201807912SA (en) Vaccine against rsv
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201907769XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201809029RA (en) Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
SG11201407548UA (en) Treatment of amd using aav sflt-1
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201903353WA (en) Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same